Perrigo Company plc (NYSE:PRGO – Get Free Report) announced a quarterly dividend on Thursday, February 19th. Shareholders of record on Monday, March 2nd will be given a dividend of 0.29 per share on Tuesday, March 24th. This represents a c) annualized dividend and a yield of 7.8%. The ex-dividend date of this dividend is Monday, March 2nd.
Perrigo has increased its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 23 consecutive years. Perrigo has a payout ratio of 35.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Perrigo to earn $3.06 per share next year, which means the company should continue to be able to cover its $1.16 annual dividend with an expected future payout ratio of 37.9%.
Perrigo Trading Up 2.2%
Shares of NYSE:PRGO traded up $0.32 during trading on Thursday, reaching $14.90. 1,771,328 shares of the company traded hands, compared to its average volume of 2,361,986. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -39.20, a P/E/G ratio of 1.30 and a beta of 0.39. Perrigo has a 52-week low of $12.17 and a 52-week high of $30.93. The company has a current ratio of 2.51, a quick ratio of 1.44 and a debt-to-equity ratio of 0.81. The business’s fifty day moving average is $14.23 and its 200-day moving average is $17.92.
Hedge Funds Weigh In On Perrigo
About Perrigo
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
Recommended Stories
- Five stocks we like better than Perrigo
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
- New gold price target
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
